This text is provided for reference. The official version is published by the Turkish Medicines and Medical Devices Agency (TİTCK).
Section I – Introduction and Scope
1.1. Introduction
Educational programmes are additional risk minimisation measures (aRMM; see GVP Module IX) and generally consist of educational materials intended to minimise an important risk and/or to optimise the benefit-risk balance of a medicinal product. The content of any educational material must be fully consistent with the product information already authorised for the medicinal product, i.e. the summary of product characteristics (SmPC), the package leaflet (PL) and the labelling, and should provide new information rather than repeat the SmPC/PL. When the development and distribution of an educational material has been approved by the relevant committees of the European Medicines Agency (EMA), the marketing authorisation holder should submit that material to the Agency for assessment and, once approved, implement it in Türkiye as well. The Agency or the marketing authorisation holder may also propose the distribution of an educational material specific to Türkiye only.
Guidance on the requirements for including the key elements of educational materials in the risk management plan (RMP) is given in GVP Module V.
This Annex to GVP Module IX gives marketing authorisation holders further guidance on submitting draft educational materials to the Agency, and also guides the Agency in assessing such materials, in particular their format and content.
1.2. Principles for educational materials
The following principles apply to educational materials:
- The need for educational materials may be agreed at the time of initial authorisation or during a regulatory procedure in the post-authorisation phase, for example after submission of a new RMP or an update of an existing RMP.
- The educational material should be specifically designed to meet the risk minimisation objectives.
- It should focus on specific safety concerns and give clear statements and concise messages describing the actions to be taken to prevent and minimise those risks.
- Educational materials must not contain, or be combined with, direct or indirect promotional elements (for example suggestive pictures and symbols).
- The marketing authorisation holder should submit a proposal to the Agency, determining which tool, content, format and level of readability are appropriate for the educational material according to the target audience. Particular effort should be made to adapt the material when patients are targeted (see GVP Module VIII).
- The marketing authorisation holder should distribute educational materials only after they have been approved by the Agency.
- A post-distribution closing report should be submitted to the Agency.
- If the medicinal product has not yet been placed on the market, the educational materials are distributed when the product is launched. In all cases, the need to distribute any educational material should be discussed with the Agency.
- The marketing authorisation holder should apply version control and ensure that only the most recently agreed version of the educational material is distributed. The date of approval by the Agency should be included in the educational material as a reference for healthcare professionals and/or patients.
- Distribution methods and the target audience are determined by the Agency.
- After approval by the Agency, the educational material prepared for the first application for an active substance is published on the Agency's website. Subsequent applications for the same active substance are prepared on the basis of the published materials and submitted to the Agency for approval.
1.3. Submission of educational materials
Draft educational material should be submitted to the Agency as follows:
- A cover letter with the following information:
- The rationale for the educational material and supporting documents (e.g. the decision of the relevant EMA committees and/or the European Commission, the Agency's opinion, the approved RMP, the assessment report identifying the need for this aRMM),
- A detailed implementation plan for the educational material, including:
- Target populations,
- Distribution method (e.g. in print, by e-mail, through social media, professional societies and/or patient associations, or publication on websites),
- Estimated time of distribution and frequency of subsequent distributions,
- Estimated launch date / date of placing on the market of the product (in the case of a new authorisation).
- A copy of the approved original material,
- The proposed material made ready for distribution in Türkiye (including pictures, charts, diagrams and video where applicable),
- The approved and/or proposed SmPC/PL,
- The most recent original SmPC/PL.
When changes in risk and/or the need for an aRMM are identified, changes to the key elements and/or to the content of the educational materials should be submitted to the Agency for approval. The revised educational material should highlight what changes have been made to the materials previously approved by the Agency.
1.4. Format and layout of educational materials
Educational materials should have an appropriate format and layout.
A title identifying the type of educational material should be given (e.g. administration guide, prescriber checklist, alert card, patient educational brochure).
The format of the educational material should include:
- The name of the medicinal product followed by the active substance(s) and/or the therapeutic class in brackets (however, if the educational material applies to several products of different marketing authorisation holders, it should refer only to the active substance and a list of the names of the medicines containing it should be attached),
- If the medicinal product is subject to additional monitoring, the inverted black equilateral triangle and the explanatory standard statement (see GVP Module II).
The material should be organised as follows:
- Bullet points should be used where appropriate to present the information clearly.
- Materials should be kept as short as possible. If an educational material is long, however, an introductory text summarising the key messages should be included. A table of contents may be considered in that case.
- Educational materials must not carry the logo of the marketing authorisation holder and/or of the product.
- For version control, every page of the educational material should carry a unique document identifier, and the date of the last revision of the text (i.e. the date of approval of the material by the Agency) should appear on the first and last page in the format "<month> <year>", unless the type of material requires exceptions (for example, a video should carry the unique document identifier at its beginning and end).
1.5. Content of educational materials
The reference documents for preparing educational materials are the RMP approved by the Agency (including its annexes), the product information and the conditions of the marketing authorisation. Depending on the regulatory procedure, the educational material should contain the messages of the key elements agreed at EU level or with the Agency and set out in the conditions of the marketing authorisation.
If the SmPC and/or PL have been made publicly available on the Agency's website or on a specific website of the marketing authorisation holder, the educational material may also refer to those web addresses. References to other websites for "further information" are only possible with the Agency's approval, for example a reference to a specific antibody test or to a video teaching the patient how to take the medicine and/or use a device. Images and graphical presentations of information should only be used when text alone is insufficient to convey the messages of the key elements, and must not be promotional (for example, the use of a specific device to administer the medicinal product).
The scope of the information in the educational material should be limited to the agreed key elements. Additional information such as efficacy data, safety comparisons with other medicinal products, or statements implying that the medicine is well tolerated or that adverse reactions occur at low frequency should not be included. In specific situations, however, the Agency may consider including efficacy data provided that this is duly justified by the marketing authorisation holder. Reference to other medicinal products outside the scope of the educational material is not permitted.
A statement encouraging the reporting of any suspected adverse reaction, and information on how to report, should also be included.
1.6. Assessment and publication of educational materials by the Agency
Timelines for the Agency's assessment of draft educational materials may vary depending, for example, on the aRMM, the type of educational material requested or the quality of the drafts submitted. An average timeline of 60 days is nevertheless considered sufficient for the assessment.
In the interest of public health, the Agency will publish the educational materials it approves on its website.
The marketing authorisation holder alone is responsible for providing the Agency with the most recent agreed versions of the educational materials.
1.7. Publication of educational materials on a specific website of the marketing authorisation holder
The marketing authorisation holder may publish educational materials on a specifically dedicated or other appropriate website, provided that:
- The way in which the information is disseminated through the website (as a primary or additional distribution route) is agreed with the Agency.
- The website address is notified to the Agency.
- A declaration that the information on the website is identical to the educational material approved by the Agency is submitted to the Agency.
- All elements and information on the specific website are in Turkish.
- Reference may be made to other relevant documents such as the SmPC, PL and the RMP summary.
- The specific website must not contain any reference to documents not approved by the Agency, or to other websites/pages or web links. The specific website must not contain references to, or information on, medicinal products not authorised in Türkiye.
Revision history
| Revision No | Revision date | Reason and explanation |
|---|---|---|
| 1 | 15.11.2022 | Format updated |
